Trial · NCT03034772
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
NCT03034772, Phase 2, Phase 3, Completed, Wills Eye; results first posted 2020-06-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration. Trials, record NCT03034772. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03034772
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
- NCT number
- NCT03034772
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 52 participants, actual
- Lead sponsor
- Wills Eye
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- Dorzolamide-timolol, Artificial tears
- First posted
- 2017-01-27
- Last updated
- 2020-06-19
- Results first posted
- 2020-06-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Mean Central Subfield Thickness (CST) | Baseline and 18 weeks | Change in mean CST on spectral domain optical coherence tomography from baseline to the final visit |
| Secondary | Change in Mean Maximum Subretinal Fluid (SRF) Height | Baseline and 18 weeks | Change in mean maximum SRF height on spectral domain optical coherence tomography from baseline to final visit. |
| Secondary | Change in Mean Maximum Pigment Epithelial Detachment (PED) Height | Baseline and 18 weeks | Change in mean maximum PED height on spectral domain optical coherence tomography from baseline to final visit. |
| Secondary | Change in Visual Acuity | Baseline and 18 weeks | Change in mean best available visual acuity from baseline to final visit. |
| Secondary | Change in Mean Intraocular Pressure (IOP) | Baseline and 18 weeks | Change in mean IOP from baseline to final visit. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Mean Central Subfield Thickness (CST) | Baseline and 18 weeks | microns | MEAN | |
| SECONDARY | Change in Mean Maximum Subretinal Fluid (SRF) Height | Baseline and 18 weeks | microns | MEAN | |
| SECONDARY | Change in Mean Maximum Pigment Epithelial Detachment (PED) Height | Baseline and 18 weeks | microns | MEAN | |
| SECONDARY | Change in Visual Acuity | Baseline and 18 weeks | logMAR | MEAN | |
| SECONDARY | Change in Mean Intraocular Pressure (IOP) | Baseline and 18 weeks | mm Hg | MEAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Mean Central Subfield Thickness (CST) | Dorzolamide-timolol | -36.6 | Standard Deviation 54 | microns | |
| Change in Mean Central Subfield Thickness (CST) | Artificial Tears | 1.7 | Standard Deviation 52.3 | microns | |
| Change in Mean Maximum Subretinal Fluid (SRF) Height | Dorzolamide-timolol | -49.4 | Standard Deviation 55 | microns | |
| Change in Mean Maximum Subretinal Fluid (SRF) Height | Artificial Tears | -22.2 | Standard Deviation 56 | microns | |
| Change in Mean Maximum Pigment Epithelial Detachment (PED) Height | Dorzolamide-timolol | -39.1 | Standard Deviation 65 | microns | |
| Change in Mean Maximum Pigment Epithelial Detachment (PED) Height | Artificial Tears | 1.1 | Standard Deviation 16 | microns | |
| Change in Visual Acuity | Dorzolamide-timolol | 0.031 | Standard Deviation 0.15 | logMAR | |
| Change in Visual Acuity | Artificial Tears | 0.018 | Standard Deviation 0.16 | logMAR | |
| Change in Mean Intraocular Pressure (IOP) | Dorzolamide-timolol | -1.81 | Standard Deviation 3.8 | mm Hg | |
| Change in Mean Intraocular Pressure (IOP) | Artificial Tears | -0.78 | Standard Deviation 2.8 | mm Hg |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dorzolamide-timolol | 27 | |
| Overall Study | STARTED | Artificial Tears | 25 | |
| Overall Study | COMPLETED | Dorzolamide-timolol | 27 | |
| Overall Study | COMPLETED | Artificial Tears | 23 | |
| Overall Study | NOT COMPLETED | Dorzolamide-timolol | 0 | |
| Overall Study | NOT COMPLETED | Artificial Tears | 2 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eyelid edema | Eye disorders | Dorzolamide-timolol | 0 | 27 | 0 |
| other | Eyelid edema | Eye disorders | Artificial Tears | 1 | 25 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dorzolamide-timolol | 0 | 27 |
| Total, all-cause mortality | Artificial Tears | 0 | 25 |
| Total, other adverse events | Dorzolamide-timolol | 0 | 27 |
| Total, other adverse events | Artificial Tears | 1 | 25 |
| Total, serious adverse events | Dorzolamide-timolol | 0 | 27 |
| Total, serious adverse events | Artificial Tears | 0 | 25 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Dorzolamide-timolol vs Artificial Tears: deaths from any cause | Trial comparisons |
| Dorzolamide-timolol vs Artificial Tears: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03034772
GET https://conductscience.org/api/trials/v1/NCT03034772/registered